Tumor Infiltrating Lymphocyte Therapy Market

According to Stratistics MRC, the Global Tumor-Infiltrating Lymphocyte Therapy Market is accounted for $0.8 billion in 2026 and is expected to reach $5.2 billion by 2034 growing at a CAGR of 26.4% during the forecast period. The Tumor-Infiltrating Lymphocyte Therapy Market encompasses personalized cancer immunotherapies that isolate tumor-reactive lymphocytes from patient tumor tissue, expand them outside the body, and reinfuse them to target malignant cells. Increasing cancer prevalence, growing demand for individualized treatments, and advancements in adoptive cell therapy are supporting market development. Innovations in lymphocyte expansion, gene engineering, and neoantigen selection improve therapeutic potential. Expanding clinical research and specialized treatment infrastructure create additional opportunities.

Market Dynamics:

Driver:

Increasing demand for personalized cancer immunotherapies and advancements in adoptive cell therapy

Increasing demand for personalized cancer immunotherapies and advancements in adoptive cell therapy are driving market growth. Rising incidence of advanced solid tumors and limitations of conventional treatments encourage development of tumor-infiltrating lymphocyte therapies. These approaches utilize immune cells isolated from patient tumors and expanded to enhance antitumor activity. Clinical progress in melanoma treatment has strengthened interest in TIL-based immunotherapy. Advancements in cell expansion, manufacturing automation, and patient selection improve therapeutic development. Growing oncology investment further supports market expansion.

Restraint:

Complex manufacturing processes and high treatment costs

Complex manufacturing processes and high treatment costs restrain market growth. TIL therapy requires surgical tumor tissue collection, specialized cell isolation, ex vivo expansion, and individualized manufacturing. Treatment typically involves lymphodepleting chemotherapy and supportive care, creating additional clinical complexity. Manufacturing timelines, variable cell yields, and specialized facility requirements may limit patient accessibility. High production expenses and reimbursement uncertainties create financial barriers. Limited availability of trained personnel and accredited treatment centers further restricts adoption across developing healthcare markets.

Opportunity:

Expansion of engineered TIL therapies and combination cancer treatment strategies

Expansion of engineered TIL therapies and combination cancer treatment strategies presents significant growth opportunities. Biotechnology companies are investigating genetically modified lymphocytes, enhanced cytokine signaling, and neoantigen-selected cell populations to improve therapeutic activity. Growing research in lung, cervical, colorectal, and head and neck cancers encourages pipeline diversification. Combining TIL therapy with immune checkpoint inhibitors may help address tumor immune resistance. Advances in cell manufacturing and targeted patient selection are expected to accelerate clinical development and potential commercialization.

Threat:

Treatment-related toxicity and competition from alternative cellular immunotherapies

Treatment-related toxicity and competition from alternative cellular immunotherapies pose significant challenges to market development. TIL therapy may involve adverse effects associated with lymphodepleting chemotherapy, cytokine administration, and intensive treatment procedures. Variable tumor tissue quality and inconsistent lymphocyte expansion can affect manufacturing outcomes. CAR-T cell therapies, T-cell receptor therapies, checkpoint inhibitors, and antibody-based immunotherapies provide competing treatment options. Regulatory scrutiny, manufacturing capacity constraints, and uncertain reimbursement policies may further influence market access and commercialization.

Covid-19 Impact:

The COVID-19 pandemic disrupted oncology services through delayed surgeries, restricted hospital admissions, and interruptions in clinical trials and cellular therapy manufacturing. Patients undergoing intensive immunotherapy faced additional concerns related to infection exposure and treatment continuity. These challenges affected tumor tissue collection, specialized laboratory operations, and patient enrollment. However, biotechnology companies adopted modified clinical protocols and strengthened manufacturing resilience. Post-pandemic recovery in cancer treatment services and expanding investment in advanced cell therapies continue to support TIL therapy development.

The conventional autologous TIL therapy segment is expected to be the largest during the forecast period

The conventional autologous TIL therapy segment is expected to account for the largest market share during the forecast period due to established clinical development and regulatory progress in advanced melanoma treatment. This approach isolates tumor-reactive lymphocytes from a patient's own tumor tissue, expands them under controlled manufacturing conditions, and reinfuses them following lymphodepleting chemotherapy. Growing clinical experience and specialized oncology infrastructure encourage adoption. Advancements in cell expansion protocols and manufacturing standardization improve treatment feasibility. Expanding patient access initiatives further strengthen segment growth.

The gene editing & engineering segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the gene editing & engineering segment is predicted to witness the highest growth rate due to increasing investigation of genetically modified tumor-infiltrating lymphocytes. These technologies aim to improve lymphocyte persistence, antitumor activity, and resistance to immunosuppressive tumor environments. Growing research into CRISPR-based modification, cytokine enhancement, and immune checkpoint pathway engineering encourages innovation. Advances in cell processing and molecular characterization could support clinical translation. Safety validation, manufacturing reproducibility, and regulatory approval remain essential for commercialization.

Region with largest share:

During the forecast period, North America is expected to hold the largest market share due to advanced oncology infrastructure, significant biotechnology investment, and established cellular therapy research capabilities. The United States supports TIL therapy development through specialized cancer centers, clinical trial networks, and commercial cell therapy manufacturing facilities. Regulatory progress in melanoma treatment and growing demand for personalized immunotherapies encourage regional market development. Strong pharmaceutical partnerships and expanding treatment center networks further strengthen North America's position.

Region with highest CAGR:

Over the forecast period, Asia Pacific is anticipated to exhibit the highest CAGR, supported by expanding oncology infrastructure, increasing cancer treatment demand, and growing investment in advanced cellular immunotherapies. China, Japan, South Korea, India, and Australia are advancing adoptive cell therapy research and specialized manufacturing capabilities. Government-supported biotechnology initiatives and expanding clinical trial activity encourage innovation. Improvements in cell processing technologies, healthcare accessibility, and oncology treatment infrastructure are expected to accelerate regional market growth.

Key players in the market

Some of the key players in the Tumor-Infiltrating Lymphocyte Therapy Market include Iovance Biotherapeutics, Inc., Obsidian Therapeutics, Inc., Instil Bio, Inc., Turnstone Biologics Corp., Lyell Immunopharma, Inc., Achilles Therapeutics plc, KSQ Therapeutics, Inc., Intima Bioscience, Inc., AgonOx, Inc., PACT Pharma, Inc., Grit Biotechnology, Shanghai Gencells Therapeutics, Shanghai OriginCell Therapeutics, Lion TCR Pte. Ltd., Bristol Myers Squibb Company, Merck & Co., Inc., Phio Pharmaceuticals Corp., and Alaunos Therapeutics, Inc.

Key Developments:

In October 2026, Iovance Biotherapeutics, Inc. announced updated Phase II IOV-LUN-202 clinical results for lifileucel in previously treated metastatic non-small cell lung cancer. The company reported a 24.6% objective response rate among 69 patients and identified a biomarker-enriched subgroup with a 59.1% response rate. Iovance also outlined plans for a precision TIL development strategy and a potential supplemental biologics license application in 2027.

In October 2026, Obsidian Therapeutics, Inc. announced plans to present updated Phase I/II clinical findings for amsokigene autoleucel (amsoki-cel, formerly OBX-115) at the Society for Immunotherapy of Cancer annual meeting. The investigational engineered TIL therapy incorporates regulatable membrane-bound IL-15 and is being evaluated in patients with immune checkpoint inhibitor-resistant advanced melanoma. The planned presentation includes updated safety and efficacy assessments.

In September 2026, Lyell Immunopharma, Inc. announced completion of a manufacturing transfer for LYL273 and provided an updated development timeline for its Phase I/II clinical trial in metastatic colorectal cancer. The development reflects continued investment in advanced T-cell immunotherapy manufacturing and clinical development for solid tumors.

Therapy Types Covered:
• Conventional Autologous TIL Therapy
• Genetically Engineered TIL Therapy
• Cytokine-Enhanced TIL Therapy
• Other Therapy Types

Technologies Covered:
• Conventional TIL Expansion
• Rapid Expansion Protocol (REP)
• Gene Editing & Engineering
• Neoantigen-Selected TIL Technology
• Other Technologies

Treatment Approaches Covered:
• TIL Monotherapy Regimens
• TIL Therapy with Immune Checkpoint Inhibitors
• TIL Therapy with Other Combination Treatments
• Other Treatment Approaches

Applications Covered:
• Melanoma
• Non-Small Cell Lung Cancer
• Cervical Cancer
• Head & Neck Cancer
• Colorectal Cancer
• Breast Cancer
• Other Applications

End Users Covered:
• Hospitals & Specialty Clinics
• Cancer Treatment Centers
• Academic Medical Centers
• Other End Users

Regions Covered:
• North America
o United States
o Canada
o Mexico
• Europe
o United Kingdom
o Germany
o France
o Italy
o Spain
o Netherlands
o Belgium
o Sweden
o Switzerland
o Poland
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
o Indonesia
o Thailand
o Malaysia
o Singapore
o Vietnam
o Rest of Asia Pacific
• South America
o Brazil
o Argentina
o Colombia
o Chile
o Peru
o Rest of South America
• Rest of the World (RoW)
o Middle East
 Saudi Arabia
 United Arab Emirates
 Qatar
 Israel
 Rest of Middle East
o Africa
 South Africa
 Egypt
 Morocco
 Rest of Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances